Cethromycin

Cethromycin

Clinical data
Routes of administration	Oral
Legal status
Legal status	Phase III Clinical Trials in US
Identifiers
IUPAC name (1S, 2R, 5R, 7R, 8R, 9S, 11R, 13R, 14R) -8- [(2S, 3R, 4S, 6R) -4- Dimethylamino -3- hydroxy -6- methyloxan -2-yl] oxy-2-ethyl-1, 5, 7, 9, 11, 13-hexamethyl -9- [(E) -3- quinolin -3- ylprop -2- enoxy] -3, 17-dioxa -15-azabicyclo [12.3.0]heptadecane -4, 6, 12, 16-tetrone
CAS Number	205110-48-1
PubChem CID	5282045
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C42H59N3O10
Molar mass	765.931 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cethromycin (initially known as ABT-773) is a macrolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On April 10, 2008, Advanced Life Sciences announced that, based on a productive meeting with the U.S. Food and Drug Administration (FDA), it plans to submit a New Drug Application (NDA) in the third quarter of 2008 for cethromycin to treat mild-to-moderate community acquired pneumonia.